Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 12;14(1):136.
doi: 10.1038/s41408-024-01119-2.

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

Arushi Khurana  1 , Allison C Rosenthal  2 , Razan Mohty  3 , Mamatha Gaddam  1 , Radhika Bansal  1 , Matthew A Hathcock  1 , Adrienne N Nedved  4 , Urshila Durani  1 , Madiha Iqbal  3 , Yucai Wang  1 , Jonas Paludo  1 , J C Villasboas  1 , David Dingli  1 , Taxiarchis Kourelis  1 , Nelson Leung  5 , Hassan Alkhateeb  1 , Michael W Ruff  6 , Alice Gallo de Moraes  7 , Paschalis Vergidis  8 , Joerg Herrmann  9 , Saad S Kenderian  1 , N Nora Bennani  1 , Patrick B Johnston  1 , Stephen M Ansell  1 , Yi Lin  10
Affiliations

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

Arushi Khurana et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.P. received research funding from Karyopharm. Y.W. received funding from Incyte, LOXO Oncology, Novartis, Genetech, and Morphosys; also had Incyte, LOXO Oncology, Eli Lilly, TG Therapeutics membership on advisory committee. Y.L. received research funding from Kite, Janssen, Celgene, Bluebird Bio, Merck, and Takeda; also received consulting fees from Janssen, Novartis, Celgene, Bluebird Bio, Juno, Legend, Sorrento, Gamida Cell, and Vineti. Also, LOXO Oncolgy, Incyte, Eli Lilly, and TG Therapeutics were taking part on an advisory committee. Stephen Ansell received from Bristol Myers Squibb, ADC Therapeutics, Seattle Genetics, Regeneron, Affimed, AITherapeutics, Pfizer, Trillium and Takeda.

References

    1. Ahmed S. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). American Society of Clinical Oncology: Journal of Clinical Oncology; 2020.
    1. Hines MR, Keenan C, Maron Alfaro G, Cheng C, Zhou Y, Sharma A, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021;194:701–7. 10.1111/bjh.17662 - DOI - PMC - PubMed
    1. Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138:2469–84. 10.1182/blood.2021011898 - DOI - PMC - PubMed
    1. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther. 2023;29:438 e1–e16.10.1016/j.jtct.2023.03.006 - DOI - PMC - PubMed
    1. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38. 10.1016/j.bbmt.2018.12.758 - DOI - PubMed

Substances

LinkOut - more resources